

**Role of Exhaled Nitric Oxide in Chronic
Obstructive Pulmonary Disease (COPD):
Correlation With Pulmonary Function Tests**

Thesis

Submitted in Partial Fulfillment of the
Requirements for
Master Degree in Chest Diseases

By

Marwa Mohammed Abd El-Rady Ahmed
M.B., B. Ch.

Supervised By

Prof. Tarek Mohamed Safwat
*Prof. of Chest Diseases
Faculty of Medicine
Ain Shams University*

Assistant Prof. Laila Ashour Helala
*Assistant Professor of Chest Diseases
Faculty of Medicine
Ain Shams University*

Assistant Prof. Magid A. El-Setouhy
*Assistant Professor of Community,
Environmental & Occupational Medicine
Faculty of Medicine
Ain Shams University*

Faculty of Medicine
AIN SHAMS UNIVERSITY
2004

Acknowledgement

Thanks first and last to **Allah**, as we owe to him for his great care, support and guidance in every step in our life. It is a great pleasure to acknowledge my deepest gratitude to **Prof. Tarek Mohamed Safwat**, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University, for his unlimited help, continuous encouragement and kind supervision.

I have the greatest pleasure to express my gratitude to **Assistant Prof. Laila Ashour Helala**, Assistant Professor of Chest Diseases, Faculty of Medicine, Ain Shams University for endless support and great assistance of this work, without her kind care, expert advice and criticism, this work would have not been accomplished.

I wish to express my deepest gratitude and appreciation to **Assistant Prof. Magid A. El-Setgouhy**, Assisant Professor of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, for his kind help, guidance and sound advice were essential for completion of this work.

Lastly grateful thanks to all my Professors of Chest Diseases and all those who give me hand in the finalization of this work.

CONTENTS

	Page
Introduction	1
Aim of the Work	
Review of Literature	
- Definitions.....	
- Epidemiology.....	
- Risk factors for COPD	
- Pathogenesis of COPD	
- Diagnosis	
- Staging of COPD	
- Nitric oxide	
- Nitric oxide in exhaled air	
- Exhaled nitric oxide in COPD	
- Exhaled nitric oxide in other pulmonary diseases	
Subjects and Methods	
Results	
Discussion	
Summary	
Conclusions	
Recommendations	
References	
Arabic Summary	

LIST OF ABBREVIATIONS

AAT	Alpha-1-antitrypsin
AHR	Airway hyperresponsiveness
ARDS	Adult respiratory distress syndrome
BAL	Bronchoalveolar lavage
BTS	British thoracic society
Ca ²⁺	Calcium
CF	Cystic fibrosis
cGMP	Cyclic guanosine monophosphate
CO ₂	Carbon dioxide
COPD	Chronic obstructive pulmonary disease
CT	Computed tomography
DNA	Deoxyribonucleic acid
DPB	Diffuse panbronchiolitis
ECP	Eosinophil cationic protein
EDRF	Endothelium derived relaxing factor
EGF	Epidermal growth factor
eNANC	Excitatory non adrenergic non cholinergic
ENO	Exhaled nitric oxide
eNOS	Endothelial nitric oxide synthase
EPO	Eosinophil peroxidase
ET-1	Endothelin-1

ETS	Environmental tobacco smoke
FEF ₂₅₋₇₅	Forced expiratory flow 25-75
FEV ₁	Forced expiratory volume in the first second
FMN	Flavin mononucleotide
FVC	Forced vital capacity
GM-CSF	Granulocyte-macrophage colony stimulating factor
H ₂ O ₂	Hydrogen peroxide
H ₄ B	Tetrahydroprotein
HDM	House dust mites
IFN- γ	Interferone- γ
IgE	Immunoglobulin E
IL-10	Interleukin-10
IL-12	Interleukin-12
IL2	Interleukin-2
IL4	Interleukin-4
IL5	Interleukin-5
IL-8	Interleukin-8
iNANC	Inhibitory non-adrenergic non-cholinergic
iNOS	inducible nitric oxide synthase
IV	Intravenous
LAA	Laboratory animal allergy
L-NAME	N ^G -nitro-L—arginine methyl ester

LTB ₄	Leukotrien B ₄
MBP	Major basic protein
MCP-1	Macrophage chemotactic protein-1
MIP-1 α	Macrophage inflammatory protein 1- α
mRNA	Messenger ribonucleic acid
NADPH	Nicotinamide adenine dinucleotide phosphate
NANC	Non-adrenergic non-cholinergic
NK	Natural killer
NMDA	N-methyl-D-aspartate
nNOS	Neuronal nitric oxide synthase
NO	Nitric oxide
NO ₂ ⁻	Nitrate
NO ₂	Nitrogen dioxide
NO ₃	Nitrite
NOS	Nitric oxide synthase
O ₃	Ozone
oNOO ⁻	Peroxynitrite
PaCO ₂	Partial pressure of oxygen in arterial blood
PaO ₂	Partial pressure of arterial CO ₂
PCD	Primary ciliary dyskinesia
PEF	Peak expiratory flow
PEFR	Peak expiratory flow rate
RS-NO	Nitrosothiols

SLP	Secretory leukoproteinase inhibitor
TGF-B	Transforming growth factor-B
TIMP ₅	Tissue inhibitors of MMP ₅
TNF	Tumor necrosis factor- α
US	United States
VC	Vital capacity
VCAM-1	Vascular cell adhesion molecule-1
VIP	Vasoactive intestinal peptide
WHO	World Health Organization

LIST OF FIGURES

No	Title	Page
1	Pathogenesis of COPD	16
2	Formation of nitric oxide	51
3	Chemical reactions of nitric oxide	60
4	Action of nitric oxide	61
5	The Flowmate spirometer	111
6	The personal sampler	112
7	The American Agency Mass Control	113
8	Nitric oxide assay procedure	116
9	Comparison between healthy smokers group (A) and control group (C) regarding the mean value of exhaled nitric oxide.	124
10	Linear regression analysis showing significant negative correlation between pack/year in the group of healthy smokers (A) and mean value of exhaled NO	125
11	Comparison between subgroup of COPD patients during exacerbation (subgroup B ₁) and control group (C) regarding the mean value of exhaled nitric oxide	126
12	Comparison between COPD patients during remission (Subgroup B ₂) and subgroup of COPD patients during exacerbation (subgroup B ₁) regarding the mean value of exhaled nitric oxide.	128

No	Title	Page
13	Comparison between smokers and ex-smokers in the subgroup of COPD patients during remission (subgroup B ₂) regarding exhaled NO value.	129
14	Comparison between the healthy smokers group (A) and subgroup of COPD during exacerbation (subgroup B ₂) regarding the mean value of exhaled nitric oxide	130
15	Linear regression analysis showing significant negative correlation between the mean value of exhaled Nitric Oxide in the subgroup of patients during exacerbation (subgroup B ₁) and FEV ₁).	131
16	Linear regression analysis showing significant negative correlation between the mean value of exhaled NO and FEV ₁ % predicted in the ex-smokers of subgroup of COPD patients during remission (subgroup B ₂).	132
17	Linear regression analysis showing significant negative correlation between the mean value of exhaled NO and FEV ₁ % predicted in the smokers of subgroup of COPD patients during remission (subgroup B ₂).	133

LIST OF TABLES

No	Title	Page
1	Sites of Inflammatory cell increases in COPD	17
2	Gold W.M Classification	43
3	Staging of COPD according to BTS	45
4	GOLD staging of COPD	46
5	GOLD staging of COPD	47
6	Characteristics of NOS isoforms	57
7	Age distribution among the studied groups	122
8	Results of the mean value of exhaled nitric oxide among the studied groups	122
9	Results of the mean value of FEV ₁ % predicted among the studied groups.	123
10	Comparison between healthy smokers group (A) and control group (C) regarding the mean value of exhaled nitric oxide.	124
11	Comparison between subgroup of COPD patients during exacerbation (subgroup B ₁) and control group (C) regarding the mean value of exhaled nitric oxide	126
12	Comparison between COPD patients during remission (Subgroup B ₂) and control group (C) regarding the mean value of exhaled NO	127

No	Title	Page
13	Comparison between COPD patients during remission (Subgroup B ₂) and subgroup of COPD patients during exacerbation (subgroup B ₁) regarding the mean value of exhaled nitric oxide.	128
14	Comparison between smokers and ex-smokers in the subgroup of COPD patients during remission (subgroup B ₂) regarding exhaled NO value.	129
15	Comparison between the healthy smokers group (A) and subgroup of COPD during exacerbation (subgroup B ₂) regarding the mean value of exhaled nitric oxide	130

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a major health problem. It is the fourth leading cause of chronic morbidity and mortality in the United States. COPD is a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases. Symptoms, functional abnormalities, and complications of COPD can all be explained on the basis on this underlying inflammation and the resulting pathology (*Global Initiative for Chronic Obstructive Lung Disease, 2004*).

Chronic inflammation is a critical feature of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. This inflammation is associated with the increased production of reactive oxygen species or oxidative stress in the lungs. Oxidative stress may have several adverse effects and may amplify the inflammatory process; however, monitoring oxidative stress is difficult and may not be reflected by changes in blood markers. Therefore they developed several noninvasive markers in the exhaled breath that may indicate oxidative stress in the lungs, and studied these in relationship to the severity of chronic inflammatory lung diseases. They analyzed the exhaled breath for the content of nitric oxide as a marker of inflammation (*Paredi et al., 2002*).

In the past nitric oxide (NO) was regarded exclusively as an atmospheric contaminant. Currently, however, it is

thought to play an important endogenous signaling role in the physiological control of airway diseases (*Gaston et al., 1994*).

NO is produced endogenously in the human respiratory tract where it can act as a dilator of bronchial and vascular smooth muscle, a neurotransmitter and an immune response mediator (*Moncada et al., 1991*).

Measurement of NO in exhaled air is a simple method of investigating endogenous NO production (*Gustafsson et al., 1991*).

NO is synthesized by various pulmonary cells, including epithelial, endothelial cells and infiltrating inflammatory cells. NO can easily be measured in exhaled air, Where its concentration depends on local production by the respiratory system (*Rolla et al., 2000*).

Exhaled NO is a well-studied marker of airway inflammation and oxidative stress and is decreased in healthy chronic smokers (*Kharitonov et al., 1995*). Exhaled NO is also increased during COPD exacerbations; whereas conflicting results have been reported in stable COPD patients. Moreover, The levels of exhaled NO were significantly correlated with lung function as assessed by FEV₁ (*Maziak et al., 1998*).

Exhaled NO levels- in COPD may be correlated with disease severity (*Clini et al., 1998*)

AIM OF THE WORK

Measurement of NO concentration in the exhaled breath of patients with chronic obstructive pulmonary disease and its value as a noninvasive marker of airway inflammation and to correlate between it and pulmonary function tests.